Asiatic Laboratories (DHA:ASIATICLAB) Debt-to-Equity: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ASIATICLAB Asiatic Laboratories Ltd DHA:ASIATICLAB
32 GF Score
Price BDT142.20
! 1 Warning Sign
View Full Analysis

What is Asiatic Laboratories Debt-to-Equity?

Asiatic Laboratories DHA:ASIATICLAB -0.56% 32 Debt-to-Equity is 0.00 as of . 20. GuruFocus rates DHA:ASIATICLAB with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 812 Drug Manufacturers companies, Asiatic Laboratories ranks worse than 123152.59% on this metric.

Asiatic Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Asiatic Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Asiatic Laboratories's Total Stockholders Equity for the quarter that ended in . 20 was BDT0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Asiatic Laboratories's Debt-to-Equity or its related term are showing as below:

DHA:ASIATICLAB's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Asiatic Laboratories  (DHA:ASIATICLAB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Asiatic Laboratories Debt-to-Equity Related Terms

Asiatic Laboratories Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Asiatic Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asiatic Laboratories Debt-to-Equity Chart

Asiatic Laboratories Annual Data
Trend
Debt-to-Equity

Asiatic Laboratories Semi-Annual Data
Debt-to-Equity

DHA:ASIATICLAB vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Asiatic Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asiatic Laboratories Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Asiatic Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Asiatic Laboratories's Debt-to-Equity falls into.


DHA:ASIATICLAB
32GF Score
Asiatic Laboratories Ltd DHA:ASIATICLAB
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Asiatic Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Asiatic Laboratories's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=( + ) / N/A
=N/A

Asiatic Laboratories's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=( + ) /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Asiatic Laboratories (DHA:ASIATICLAB) has a Debt-to-Equity of 0.00 as of . 20. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Asiatic Laboratories and its competitors. According to the industry distribution chart, Asiatic Laboratories ranks #999999 out of 812 companies in the Drug Manufacturers industry.
Is Asiatic Laboratories' Debt-to-Equity too high?
Asiatic Laboratories' current Debt-to-Equity is 0.00. Based on the distribution chart, Asiatic Laboratories ranks #999999 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Asiatic Laboratories has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Asiatic Laboratories' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Asiatic Laboratories ranks #999999 out of 812 companies for Debt-to-Equity. This places Asiatic Laboratories in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Asiatic Laboratories and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asiatic Laboratories's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asiatic Laboratories stock overvalued right now?
Asiatic Laboratories (DHA:ASIATICLAB) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Asiatic Laboratories' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Asiatic Laboratories (DHA:ASIATICLAB), the current Debt-to-Equity is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Asiatic Laboratories Business Description

Address Siddeshwari Circular Road, 42-43, Treasure Island (5 th Floor) Shantinagar, Dhaka, BGD, 1217
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.
32GF Score

Get the complete analysis for DHA:ASIATICLAB

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT142.20
Price